Sandoz enters US generic injectables market

Executive Summary

Sandoz' acquisition of Canadian generic manufacturer Sabex will give the firm entry into the U.S. sterile injectable market, the company said June 7. The injectable medicines Infufer (iron dextran) and hydromorphone are Sabex' leading U.S. products. The company makes a total of 89 Canadian generic molecules in its FDA-approved facilities. The deal also allows Sandoz to bring its solid oral generics to the Canadian market. The $565 mil. cash transaction is expected to close in July. Sandoz plans to retain the entire Sabex management team...